Hypofractionated Radiotherapy After Complete Resection for Stage II/III Thymic Epithelial Tumors (TET-HFRT40)
2026年7月8日 更新者:Tianjin Medical University Cancer Institute and Hospital
A Prospective, Single-Arm Phase II Clinical Study of Hypofractionated Adjuvant Radiotherapy After Complete Resection for Stage II/III Thymic Epithelial Tumors
This is a prospective, open-label, single-arm Phase II study designed to evaluate the safety of postoperative hypofractionated radiotherapy in patients with Stage II/III thymic epithelial tumors after complete resection.
After a screening period of up to 28 days, eligible patients will receive adjuvant hypofractionated radiotherapy to a total dose of 40 Gy in 15 fractions, delivered once daily at 2.67 Gy per fraction, 5 days per week over 3 weeks.
The study will primarily assess treatment-related safety and tolerability, with preliminary evaluation of efficacy, economic burden, and quality of life.
研究概览
研究类型
介入性
注册 (估计的)
49
阶段
- 阶段2
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Wencheng Zhang, M.D.
- 电话号码:1121 +86 022 23340123
- 邮箱:zhangwencheng@tjmuch.com
学习地点
-
-
Tianjin Municipality
-
Tianjin、Tianjin Municipality、中国、300060
- 招聘中
- Tianjin Medical University Cancer Institute and Hospital
-
接触:
- Wencheng Zhang, M.D.
- 电话号码:1121 +86 022 23340123
- 邮箱:zhangwencheng@tjmuch.com
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
描述
Inclusion Criteria:
- Patients who voluntarily agree to participate in this study, sign the informed consent form, demonstrate good compliance, and are willing to comply with scheduled follow-up visits.
- Age 18-75 years, male or female.
- Histopathologically confirmed thymoma or thymic carcinoma after R0 complete resection. Eligible disease stages according to the Masaoka-Koga staging system include Stage II-III thymic carcinoma, Stage IIA Type B3 thymoma, Stage IIB Type B2/B3 thymoma, and Stage III thymoma.
- Eastern Cooperative Oncology Group performance status of 0-1.
- Life expectancy of at least 3 months.
- Adequate major organ function to meet the requirements of study treatment, including bone marrow, hepatic, renal, and coagulation function according to protocol-specified criteria.
- Patients with reproductive potential must agree to use medically acceptable contraception during study treatment and for 6 months after completion of study treatment. Female patients of childbearing potential must have a negative pregnancy test before enrollment and must not be breastfeeding.
Exclusion Criteria:
- Patients who do not meet the protocol-specified requirements for pathological type, disease stage, or histological subtype.
- Patients who have not undergone surgical treatment, or who underwent R1 or R2 resection, or who have definite gross residual disease.
- Prior thoracic radiotherapy.
- Major surgery other than the tumor resection procedure or severe trauma within 4 weeks before the first radiotherapy treatment.
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
- Prior or ongoing non-protocol-specified antitumor therapy, including immunotherapy, targeted therapy, radiotherapy, or other investigational treatment.
- Active autoimmune disease or a history of severe autoimmune disease that, in the investigator's judgment, makes the patient unsuitable for radiotherapy.
- History of immunodeficiency, including HIV positivity, history of organ transplantation, or history of allogeneic bone marrow transplantation.
- Uncontrolled severe cardiovascular disease, such as New York Heart Association Class II or higher heart failure, unstable angina, myocardial infarction within 1 year, or severe arrhythmia requiring clinical intervention.
- Severe infection within 4 weeks before the first radiotherapy treatment, or active pulmonary inflammation indicated by baseline imaging.
- History of interstitial lung disease, history of non-infectious pneumonitis, or Grade 3 or higher pulmonary dysfunction confirmed by pulmonary function testing.
- Active pulmonary tuberculosis, active hepatitis B infection, or active hepatitis C infection.
- Diagnosis of another malignancy before the first radiotherapy treatment, except for low-risk malignancies that have been adequately treated.
- Any other condition that, in the investigator's judgment, may affect patient safety, compliance, or the collection of study data.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:RT
|
The investigational treatment consists of postoperative hypofractionated radiotherapy delivered at a total dose of 40 Gy in 15 fractions (2.67 Gy per fraction), administered 5 days per week.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of Treatment-Related Grade 2 or Higher Acute Adverse Events
大体时间:Up to 3 months
|
Percentage of participants who experience treatment-related Grade 2 or higher acute adverse events from the start of radiotherapy to 3 months after completion of radiotherapy, assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0).
|
Up to 3 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Disease-Free Survival
大体时间:Up to 3 years
|
Time from the start of radiotherapy to the first documented disease recurrence, distant metastasis, or death from any cause, whichever occurs first.
|
Up to 3 years
|
|
Overall Survival
大体时间:Up to 3 years
|
Time from the start of radiotherapy to death from any cause.
|
Up to 3 years
|
|
Locoregional Recurrence Rate
大体时间:Up to 3 years
|
ercentage of participants who develop locoregional recurrence during follow-up.
Locoregional recurrence includes recurrence in the tumor bed, mediastinum, pleura, or regional lymph nodes, as assessed by imaging, pathology, or clinical evaluation.
|
Up to 3 years
|
|
Distant Metastasis Rate
大体时间:Up to 3 years
|
Percentage of participants who develop distant metastasis during follow-up, as assessed by imaging, pathology, or clinical evaluation.
|
Up to 3 years
|
|
All-Cause Mortality Rate
大体时间:Up to 3 years
|
Percentage of participants who die from any cause during follow-up.
|
Up to 3 years
|
|
Incidence of Treatment-Related Late Adverse Events
大体时间:From 6 months after completion of radiotherapy to 3 years
|
Percentage of participants who experience treatment-related late adverse events occurring 6 months or later after completion of radiotherapy, including pulmonary, cardiac, esophageal, or other late adverse events, assessed according to NCI-CTCAE v5.0.
|
From 6 months after completion of radiotherapy to 3 years
|
|
Total Economic Cost
大体时间:Up to 3 years
|
Total economic cost per participant during the study period, including direct medical costs, non-medical costs, and indirect costs.
Direct medical costs include radiotherapy costs, radiotherapy-related symptomatic treatment costs, and costs for the management of toxic and adverse reactions.
Non-medical and indirect costs include transportation costs, accommodation costs, and lost work or companion time costs.
Costs will be calculated in Chinese Yuan.
|
Up to 3 years
|
|
Quality of Life Score Assessed by EORTC QLQ-C30
大体时间:Up to 3 years
|
Quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30).
The global health status/quality of life score will be recorded at baseline and predefined follow-up visits.
Scores range from 0 to 100, with higher scores indicating better global health status/quality of life.
|
Up to 3 years
|
|
Swallowing Function Score Assessed by the Standardized Swallowing
大体时间:Up to 3 years
|
Swallowing function will be assessed using the Standardized Swallowing Assessment (SSA).
The total SSA score will be recorded at baseline and predefined follow-up visits, with higher scores indicating worse swallowing function.
|
Up to 3 years
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Odds Ratios for Cardiac-Related Disease Occurrence According to Predefined Cardiac and Coronary Artery Dose Parameters
大体时间:From baseline to up to 3 years after radiotherapy
|
Odds ratios for cardiac-related disease occurrence per 1-Gy increase in predefined cardiac and coronary artery dose parameters will be estimated using logistic regression.
Predefined dose parameters will include mean heart dose and coronary artery substructure dose parameters, measured in Gray (Gy) from the radiotherapy treatment plan.
Cardiac-related disease occurrence will be defined as the occurrence of clinically diagnosed cardiac disease or cardiac adverse events during follow-up, assessed by clinical cardiac evaluation and NCI-CTCAE v5.0.
Cardiac-related diseases or adverse events may include coronary artery disease, myocardial ischemia or infarction, arrhythmia, heart failure, pericardial disease, or other clinically diagnosed cardiac events.
|
From baseline to up to 3 years after radiotherapy
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Wencheng Zhang, M.D.、Tianjin Medical University Cancer Institute and Hospital
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (估计的)
2026年7月14日
初级完成 (估计的)
2027年6月30日
研究完成 (估计的)
2029年6月30日
研究注册日期
首次提交
2026年7月1日
首先提交符合 QC 标准的
2026年7月8日
首次发布 (实际的)
2026年7月9日
研究记录更新
最后更新发布 (实际的)
2026年7月10日
上次提交的符合 QC 标准的更新
2026年7月8日
最后验证
2026年7月1日
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- E20260837
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
不
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.